An autotaxin inhibitor PAT-505 reduced fibrosis in mouse models of NASH and an ATX inhibitor AM063 and an LPAR1 antagonist AM095 decreased fibrosis and reduced HCC development in a diethylnitrosamine (DEN)-induced HCC model [292,293]. Here, ENPP2 is linked to metabolic dysfunction-associated steatohepatitis.